Among individuals with HFpEF and obesity, incretin-based therapies were associated with a statistically significant reduction in time to first HF hospitalization/event using the DL model, which persisted in sensitivity analyses using both the REML-modified HK and REML-Wald models. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.